Menu
Back to Journals » Research and Reports in Urology » Volume 2
Pazopanib and anti-VEGF therapy
Authors Drabkin H
Published 12 March 2010 Volume 2010:2 Pages 35—40
DOI https://doi.org/10.2147/RRU.S5896
Review by Single anonymous peer review
Peer reviewer comments 2
Harry A Drabkin
Medical University of South Carolina and Hollings Cancer Center, Charleston, SC, USA
Abstract: Pazopanib (VotrientTM, GlaxoSmithKline), a multi-kinase inhibitor with activity against VEGFR and other receptors, was recently approved by the FDA for the treatment of advanced renal cell carcinoma (RCC). Here, we review the history of its development, together with an overview of VEGF and its receptors and co-receptors. Results from selected clinical trial data in RCC and other malignant diseases are presented. Based on available evidence, pazopanib is an effective VEGFR inhibitor with demonstrable clinical activity in metastatic RCC and promising activity in other diseases. Like most kinase inhibitors, its activity is not restricted to VEGF receptors, which is reflected in its side-effect profile.
Keywords: pazopanib, VEGFR, renal cell carcinoma
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.